Search

everythinglearnresearchcommunity

for

Search:↓

Ashwagandha may cause hair thinning due to increased TSH levels, suggesting a link to hypothyroidism. Users are advised to consult a doctor for proper evaluation.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

The conversation discusses using minoxidil, finasteride, spironolactone, and RU58841 for hair loss treatment. Users share experiences with these treatments, noting side effects and varying effectiveness.

A 33-year-old male experienced sudden, rapid hair loss, possibly due to a reaction to mentholated shampoo and undiluted tea tree oil, with a history of seborrheic dermatitis. He is currently taking finasteride, vitamin D3, a multivitamin, and biotin, and is seeking further medical evaluation.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

New hair loss treatments like Shiseido/Replicel and Histogen were discussed, with cautious optimism about their availability by 2018. Setipiprant, Replicel, and Bimatoprost were mentioned as potential treatments expected around 2016-2017.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.

Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.

A 33-year-old man experienced diffuse thinning and hair shedding due to sleep deprivation and low testosterone. After starting hCG treatment, he noticed hair regrowth on his temples.

A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.

A 16-year-old is experiencing thinning hair at the front and shedding during showers. He is concerned about potential early baldness and is considering seeing a doctor and taking multivitamins.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.

A new hair loss treatment using dermal exosomes can restore up to 90% of lost hair in mice. Users discuss potential human trials and compare it to Minoxidil and Finasteride.

OP is experiencing significant hair loss despite GFC and PRP treatments and has abnormal lab results. They are advised to consult a hair-focused dermatologist for further evaluation.

Glycine may upregulate 5AR, potentially affecting hair. Users suggest using Finasteride to manage hair loss concerns.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.